Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18481410 | 0.94 | USP7 (1.00) | USP7USP47 | |
| SCHEMBL2680022 | 0.91 | USP7 (1.00) | USP7USP47 | |
| SCHEMBL2681325 | 0.87 | USP7 (0.77) | USP7USP47 | |
| SCHEMBL2680172 | 0.86 | USP7 (0.77) | USP7USP47 | |
| SCHEMBL2681252 | 0.85 | USP7 (0.75) | USP7USP47 | |
| SCHEMBL2680616 | 0.85 | USP7 (0.75) | USP7USP47 | |
| SCHEMBL2680397 | 0.85 | USP7 (0.75) | USP7USP47 | |
| SCHEMBL2681045 | 0.85 | USP7 (0.82) | USP7USP47 | |
| SCHEMBL18445966 | 0.84 | USP7 (0.73) | USP7USP47 | |
| SCHEMBL2679816 | 0.84 | USP7 (0.83) | USP7USP47 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10292973-B2 | Covalent irreversible inhibitors of USP7 as anti-cancer agents | PROGENRA, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-10292973-B2 | Covalent irreversible inhibitors of USP7 as anti-cancer agents | PROGENRA, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-9717717-B1 | Methods of treating cancer through the inhibition of USP7 and immune system modulation | PROGENRA, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9717717-B1 | Methods of treating cancer through the inhibition of USP7 and immune system modulation | PROGENRA, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| WO-2017023684-A2 | COVALENT IRREVERSIBLE INHIBITORS OF USP7 AS ANTI-CANCER AGENTS | PROGENRA, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023684-A2 | COVALENT IRREVERSIBLE INHIBITORS OF USP7 AS ANTI-CANCER AGENTS | PROGENRA, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10292973-B2 | Covalent irreversible inhibitors of USP7 as anti-cancer agents | USP7, USP2, USP28 | USP7 1/4885USP47 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.